

(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11)

**EP 1 334 731 A1**

(12)

**EUROPEAN PATENT APPLICATION**

published in accordance with Art. 158(3) EPC

(43) Date of publication:  
13.08.2003 Bulletin 2003/33

(51) Int Cl.7: **A61K 45/00**, A61K 39/395,  
A61P 17/06

(21) Application number: 01978921.3

(86) International application number:  
PCT/JP01/09409

(22) Date of filing: 25.10.2001

(87) International publication number:  
WO 02/034292 (02.05.2002 Gazette 2002/18)

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU**  
**MC NL PT SE TR**  
Designated Extension States:  
**AL LT LV MK RO SI**

(30) Priority: 25.10.2000 JP 2000325904

(71) Applicant: **CHUGAI SEIYAKU KABUSHIKI**  
**KAISHA**  
Tokyo, 115-8543 (JP)

(72) Inventors:  
• **ITO, Hiroaki**  
Ashiya-shi, Hyogo 659-0028 (JP)  
• **YOSHIZAKI, Kazuyuki**  
Ashiya-shi, Hyogo 659-0042 (JP)  
• **NISHIMOTO, Norihiro**  
Minoh-shi, Osaka 562-0011 (JP)

- **KISHIMOTO, Tadamitsu**  
Tondabayashi-shi, Osaka 584-0021 (JP)
- **SHIMAOKA, Shin**, C/O **CHUGAI SEIYAKU K.K.**  
Gotenba-shi, Shizuoka 412-8513 (JP)
- **KITAMURA, Hidetomo**,  
C/O **CHUGAI SEIYAKU K.K.**  
Gotenba-shi, Shizuoka 412-8513 (JP)
- **SUGIMOTO, Masamichi**,  
C/O **CHUGAI SEIYAKU K.K.**  
Gotenba-shi, Shizuoka 412-8513 (JP)
- **AKAMATSU, Kenichi**,  
C/O **CHUGAI SEIYAKU K.K.**  
Gotenba-shi, Shizuoka 412-8513 (JP)

(74) Representative: **HOFFMANN EITLE**  
**Patent- und Rechtsanwälte**  
**Arabellastrasse 4**  
**81925 München (DE)**

(54) **PREVENTIVES OR REMEDIES FOR PSORIASIS CONTAINING AS THE ACTIVE INGREDIENT IL-6 ANTAGONIST**

(57) A preventive and therapeutic agent for psoriasis comprising an interleukin-6 (IL-6) antagonist such as, for example, an antibody against IL-6 receptor.

**EP 1 334 731 A1**

## Description

## Technical Field

- 5 [0001] The present invention relates to a preventive or therapeutic agent comprising an interleukin-6 (IL-6) antagonist as an active ingredient.

## Background Art

- 10 [0002] IL-6 is a cytokine called B-cell stimulating factor 2 (BSF2) or interferon  $\beta$ 2. IL-6 was discovered as a differentiation factor responsible for activation of B-lymphatic cells (Hirano, T. et al., Nature (1986) 324, 73-76). Thereafter, it was found to be a multifunctional cytokine that influences the function of various cells (Akira, S. et al., Adv. in Immunology (1993) 54, 1-78). IL-6 has been reported to induce the maturing of T lymphatic cells (Lotz, M. et al., J. Exp. Med. (1988) 167, 1253-1258).
- 15 [0003] IL-6 propagates its biological activity through two proteins on the cell. One of them is a ligand-binding protein with a molecular weight of about 80 kD to which IL-6 binds (Taga T. et al., J. Exp. Med. (1987) 166, 967-981; Yamasaki, K. et al., Science (1987) 241, 825-828). IL-6 receptor occurs not only in a membrane-bound form that penetrates and is expressed on the cell membrane but also as a soluble IL-6 receptor consisting mainly of the extracellular region.
- 20 [0004] The other is non-ligand-binding membrane-bound protein gp130 with a molecular weight of about 130 kD that takes part in signal transduction. IL-6 and IL-6 receptor form an IL-6/IL-6 receptor complex, to which gp130 is bound, and thereby the biological activity of IL-6 is propagated into the cell (Taga et al., Cell (1989) 58, 573-581).
- [0005] IL-6 antagonists are substances that inhibit the transduction of IL-6 biological activities. Up to now, there have been known antibodies to IL-6 (anti-IL-6 antibodies), antibodies to IL-6 receptor (anti-IL-6 receptor antibodies), antibodies to gp130 (anti-gp130 antibodies), reshaped IL-6, IL-6 or IL-6 receptor partial peptides, and the like.
- 25 [0006] Antibodies to IL-6 receptor have been described in a number of reports (Novick D. et al., Hybridoma (1991) 10, 137-146; Huang, Y.W. et al., Hybridoma (1993) 12, 621-630; International Patent Application WO 95-09873; French Patent Application FR 2694767; United States Patent US 5216128). A humanized PM-1 antibody was obtained by implanting the complementarity determining region (CDR) of a mouse antibody PM-1 (Hirata et al., J. Immunology (1989), one of anti-IL-6 receptor antibodies, 143, 2900-2906) into a human antibody (International Patent Application
- 30 WO 92-19759) has been known.
- [0007] Generally psoriasis is a chronic and intractable dermatosis, and has an appearance in which white or silver white keratin has been formed on red-colored (erythema) circular or elliptic protrusions. Psoriasis is a typical dermatosis of erythroscummatous dermatoses, and this erythroscummatous dermatoses is a cutaneous symptom in which "inflammation" resulting from the invasion of leukocytes such as lymphocytes into the skin, and "keratosis" in which the epi-
- 35 dermis and the horny layer of the skin become thick are simultaneously present.
- [0008] Although psoriasis is divided into psoriasis vulgaris, psoriatic arthritis, pustular psoriasis, palmoplantar pustulosis, and psoriasis guttata by symptom, the etiology and the mechanism of onset have not been elucidated. However, the fact that cyclosporine having a lymphocyte-suppressing activity has a therapeutic effect on psoriasis led to the hypothesis that lymphocytes are involved.
- 40 [0009] Known therapeutic agents for psoriasis include steroids for external use, cyclosporine for internal use, methotrexate for internal use, UV therapy, etc. for controlling the inflammation of the skin; vitamin D for external use, retinoids (Tigason) for internal use, UV therapy, etc. for controlling the growth (keratosis) of the epidermis; nonsteroidal anti-inflammatory drugs (for arthritis of psoriatic arthritis), antibiotics (for related infections), etc. for treating other individual related conditions.
- 45 [0010] However, there have been no attempts so far to control specifically the biological activity of IL-6 using IL-6 antagonists such as anti-IL-6 receptor antibody in psoriasis, and it was not known that IL-6 antagonists such as anti-IL-6 receptor antibody exhibits a therapeutic effect for psoriasis.

## Disclosure of the Invention

- 50 [0011] It is an object of the present invention to provide a new type of preventive or therapeutic agent for psoriasis.
- [0012] Thus, the present invention provides (1) a preventive or therapeutic agent for psoriasis comprising an IL-6 antagonist as an active ingredient.
- [0013] The present invention also provides (2) a preventive or therapeutic agent for psoriasis comprising an antibody
- 55 against IL-6 receptor as an active ingredient.
- [0014] The present invention also provides (3) a preventive or therapeutic agent for psoriasis comprising a monoclonal antibody against IL-6 receptor as an active ingredient.
- [0015] The present invention also provides (4) a preventive or therapeutic agent for psoriasis comprising a mono-

clonal antibody against human IL-6 receptor as an active ingredient. The monoclonal antibody against human IL-6 receptor is preferably PM-1 antibody.

[0016] The present invention also provides (5) a preventive or therapeutic agent for psoriasis comprising a monoclonal antibody against mouse IL-6 receptor as an active ingredient. The monoclonal antibody against mouse IL-6 receptor is preferably MR16-1 antibody.

[0017] The present invention also provides (6) a preventive or therapeutic agent for psoriasis comprising a recombinant antibody against IL-6 receptor as an active ingredient. The recombinant antibody against IL-6 receptor preferably has the constant region (C region) of a human antibody.

[0018] The present invention also provides (7) a preventive or therapeutic agent for psoriasis comprising a chimeric antibody or a humanized antibody against IL-6 receptor as an active ingredient.

[0019] The present invention also provides (8) a preventive or therapeutic agent for psoriasis comprising a humanized PM-1 antibody as an active ingredient.

#### Best Mode for Carrying Out the Invention

[0020] IL-6 antagonists for use in the present invention may be of any origin, any type, and any form, as long as they exhibit preventive or therapeutic effects on psoriasis.

[0021] IL-6 antagonists are substances that block signal transduction by IL-6 and inhibit the biological activity of IL-6. IL-6 antagonists are substances that preferably have an inhibitory action to the binding to any of IL-6, IL-6 receptor or gp130. As IL-6 antagonists, there can be mentioned, for example, anti-IL-6 antibody, anti-IL-6 receptor antibody, anti-gp130 antibody, reshaped IL-6, soluble reshaped IL-6 receptor, or partial peptides of IL-6 or IL-6 receptor, as well as low molecular weight substances that exhibit activities similar to them.

[0022] Anti-IL-6 antibodies for use in the present invention can be obtained as polyclonal or monoclonal antibodies using a known method. As the anti-IL-6 antibodies for use in the present invention, monoclonal antibodies of, in particular, mammalian origin are preferred. Monoclonal antibodies of a mammalian origin include those produced by a hybridoma and those produced by a host which has been transformed by gene engineering technology with an expression vector containing the antibody gene. These antibodies, via binding to IL-6, block the binding of IL-6 to IL-6 receptor, and thereby block the propagation of biological activity of IL-6 into the cell.

[0023] Examples of such antibodies include MH166 antibody (Matsuda, et al., Eur. J. Immunology (1988) 18, 951-956), or SK2 antibody (Sato, et al., The 21st General Meeting of the Japanese Society for Immunology, Gakujutu Kiroku (1991) 21, 166) etc.

[0024] A hybridoma that produces anti-IL-6 antibody can be basically constructed using a known procedure as described below. Thus, IL-6 is used as a sensitizing antigen, which is immunized in the conventional method of immunization, and the immune cells thus obtained are fused with known parent cells in a conventional cell fusion process, followed by a conventional screening method to screen monoclonal antibody-producing cells.

[0025] Specifically, anti-IL-6 antibodies may be obtained in the following manner. For example, human IL-6 to be used as the sensitizing antigen for obtaining antibody can be obtained using the IL-6 gene / amino acid sequence disclosed in Eur. J. Biochem. (1987) 168, 543-550; J. Immunol. (1988) 140, 1534-1541, or Agr. Biol. Chem. (1990) 54, 2685-2688.

[0026] After the gene sequence of IL-6 was inserted into a known expression vector to transform a suitable host cell, the IL-6 protein of interest may be purified from the host cell or a culture supernatant thereof by a known method, and the purified IL-6 protein may be used as the sensitizing antigen. Alternatively, a fusion protein of the IL-6 protein and another protein may be used as the sensitizing antigen.

[0027] Anti-IL-6 receptor antibodies for use in the present invention can be obtained as polyclonal or monoclonal antibodies using a known method. As the anti-IL-6 receptor antibodies for use in the present invention, monoclonal antibodies of, in particular, a mammalian origin are preferred. Monoclonal antibodies of a mammalian origin include those produced by a hybridoma and those produced by a host which has been transformed by gene engineering technology with an expression vector containing the antibody gene. These antibodies, via binding to IL-6, block the binding of IL-6 to IL-6 receptor, and thereby block the propagation of biological activity of IL-6 into the cell.

[0028] Examples of such antibodies include MR16-1 antibody (Tamura, T. et al., Proc. Natl. Acad. Sci. USA (1993) 90, 11924-11928), PM-1 antibody (Hirata, Y. et al., J. Immunology (1989) 143, 2900-2906), AUK12-20 antibody, AUK64-7 antibody or AUK146-15 antibody (International Patent Application WO 92-19759), and the like. Among them, PM-1 antibody is most preferred.

[0029] Incidentally, the hybridoma cell line which produces PM-1 antibody has been internationally deposited under the provisions of the Budapest Treaty as PM-1 on July 12, 1988 with the International Patent Organism Depository of the National Institute of Industrial Science and Technology (Central 6, 1-1-1 Higashi, Tsukuba City, Ibaraki Pref., 305-5466 Japan) as FERM BP-2998. Also, the hybridoma cell line which produces MR16-1 antibody has been internationally deposited under the provisions of the Budapest Treaty as Rat-mouse hybridoma MR16-1 on March 13, 1997

with the International Patent Organism Depository of the National Institute of Industrial Science and Technology (Central 6, 1-1-1 Higashi, Tsukuba City, Ibaraki Pref., 305-5466 Japan) as FERM BP-5875.

**[0030]** A hybridoma that produces anti-IL-6 receptor monoclonal antibody can, basically, be constructed using a known procedure as described below. Thus, IL-6 receptor is used as a sensitizing antigen, which is immunized in the conventional method of immunization, and the immune cells thus obtained are fused with known parent cells in a conventional cell fusion process, followed by a conventional screening method to screen monoclonal antibody-producing cells.

**[0031]** Specifically, anti-IL-6 receptor antibodies may be obtained in the following manner. For example, human IL-6 receptor used as the sensitizing antigen for obtaining antibody can be obtained using the IL-6 receptor gene / amino acid sequence disclosed in European Patent Application No. EP 325474, and mouse IL-6 receptor can be obtained using the IL-6 receptor gene / amino acid sequence disclosed in Japanese Unexamined Patent Publication (Kokai) No. 3-155795.

**[0032]** There are two types of IL-6 receptor: IL-6 receptor expressed on the cell membrane, and IL-6 receptor detached from the cell membrane (Soluble IL-6 Receptor; Yasukawa et al., J. Biochem. (1990) 108, 673-676). Soluble IL-6 receptor antibody is composed of the substantially extracellular region of IL-6 receptor bound to the cell membrane, and is different from the membrane-bound IL-6 receptor in that the former lacks the transmembrane region or both of the transmembrane region and the intracellular region. IL-6 receptor protein may be any IL-6 receptor, as long as it can be used as a sensitizing antigen for preparing anti-IL-6 receptor antibody for use in the present invention.

**[0033]** After a gene encoding IL-6 receptor has been inserted into a known expression vector system to transform an appropriate host cell, the desired IL-6 receptor protein may be purified from the host cell or a culture supernatant thereof using a known method, and the IL-6 receptor protein thus purified may be used as the sensitizing antigen. Alternatively, cells that express IL-6 receptor protein or a fusion protein of IL-6 receptor protein and another protein may be used as the sensitizing antigen.

**[0034]** Escherichia coli (E. coli) containing a plasmid pIBBSF2R that comprises cDNA encoding human IL-6 receptor has been internationally deposited under the provisions of the Budapest Treaty as HB101-pIBBSF2R on January 9, 1989 with the International Patent Organism Depository of the National Institute of Industrial Science and Technology (Central 6, 1-1-1 Higashi, Tsukuba City, Ibaraki Pref., 305-5466 Japan) as FERM BP-2232.

**[0035]** Anti-gp130 antibodies for use in the present invention can be obtained as polyclonal or monoclonal antibodies using a known method. As the anti-gp130 antibodies for use in the present invention, monoclonal antibodies of, in particular, mammalian origin are preferred. Monoclonal antibodies of a mammalian origin include those produced by a hybridoma and those produced by a host which has been transformed by gene engineering technology with an expression vector containing the antibody gene. These antibodies, via binding to gp130, block the binding of gp130 to the IL-6/IL-6 receptor complex, and thereby block the propagation of biological activity of IL-6 into the cell.

**[0036]** Examples of such antibodies include AM64 antibody (Japanese Unexamined Patent Publication (Kokai) No. 3-219894), 4B11 antibody and 2H4 antibody (US 5571513), B-S12 antibody and B-P8 antibody (Japanese Unexamined Patent Publication (Kokai) No. 8-291199) etc.

**[0037]** A hybridoma that produces anti-gp130 antibody can be basically constructed using a known procedure as described below. Thus, gp130 is used as a sensitizing antigen, which is immunized in the conventional method of immunization, and the immune cells thus obtained are fused with known parent cells in a conventional cell fusion process, followed by a conventional screening method to screen monoclonal antibody-producing cells.

**[0038]** Specifically, monoclonal antibodies may be obtained in the following manner. For example, gp130 used as the sensitizing antigen for obtaining antibody can be obtained using the gp130 gene / amino acid sequence disclosed in European Patent Application No. EP 411946.

**[0039]** The gene sequence of gp130 may be inserted into a known expression vector, and said vector is used to transform a suitable host cell. From the host cell or a culture supernatant therefrom, the gp130 protein of interest may be purified by a known method, and the purified IL-6 protein may be used as the sensitizing antigen. Alternatively, cells expressing gp130, or a fusion protein of the gp130 protein and another protein may be used as the sensitizing antigen.

**[0040]** Preferably, mammals to be immunized with the sensitizing antigen are selected in consideration of their compatibility with the parent cells for use in cell fusion and they generally include, but are not limited to, rodents such as mice, rats and hamsters.

**[0041]** Immunization of animals with a sensitizing antigen is carried out using a known method. A general method, for example, involves intraperitoneal or subcutaneous administration of a sensitizing antigen to the mammal. Specifically, a sensitizing antigen, which was diluted and suspended in an appropriate amount of phosphate buffered saline (PBS) or physiological saline etc., is mixed with an appropriate amount of a common adjuvant such as Freund's complete adjuvant. After being emulsified, it is preferably administered to a mammal several times every 4 to 21 days. Additionally, a suitable carrier may be used at the time of immunization of the sensitizing antigen.

**[0042]** After the immunization and confirmation of an increase in the desired antibody levels in the serum by a conventional method, immune cells are taken out from the mammal and are subjected to cell fusion. As preferred immune

cells that are subjected to cell fusion, there can be specifically mentioned spleen cells.

[0043] Mammalian myeloma cells as the other parent cells which are subjected to cell fusion with the above-mentioned immune cells preferably include various known cell lines such as P3x63Ag8.653 (Kearney, J.F. et al., J. Immunol. (1979) 123, 1548-1550), P3x63Ag8U.1 (Current Topics in Microbiology and Immunology (1978) 81, 1-7), NS-1 (Kohler, G. and Milstein, C., Eur. J. Immunol. (1976) 6, 511-519), MPC-11 (Margulies, D.H. et al., Cell (1976) 8, 405-415), SP2/0 (Shulman, M. et al., Nature (1978) 276, 269-270), FO (de St. Groth, S.F. et al., J. Immunol. Methods (1980) 35, 1-21), S194 (Trowbridge, I.S., J. Exp. Med. (1978) 148, 313-323), R210 (Galfre, G. et al., Nature (1979) 217, 131-133) and the like which may be used as appropriate.

[0044] Cell fusion between the above immune cells and myeloma cells may be essentially conducted in accordance with a known method such as is described in Milstein et al. (Kohler, G. and Milstein, C., Methods Enzymol. (1981) 73, 3-46) and the like.

[0045] More specifically, the above cell fusion is carried out in the conventional nutrient broth in the presence of, for example, a cell fusion accelerator. As the cell fusion accelerator, for example, polyethylene glycol (PEG), Sendai virus (HVJ) and the like may be used, and an adjuvant such as dimethyl sulfoxide may be added as desired to enhance the efficiency of fusion.

[0046] The preferred ratio of the immune cells and the myeloma cells for use is, for example, 1 to 10 times more immune cells than the myeloma cells. Examples of culture media to be used for the above cell fusion include, for example, RPMI 1640 medium and MEM culture medium suitable for the growth of the above myeloma cell lines, and the conventional culture medium used for this type of cell culture, and besides a serum supplement such as fetal calf serum (FCS) may be added.

[0047] In cell fusion, predetermined amounts of the above immune cells and the myeloma cells are mixed well in the above culture liquid, to which a PEG solution previously heated to about 37 °C, for example a PEG solution with a mean molecular weight of 1000 to 6000, is added at a concentration of 30 to 60% (w/v) and mixed to obtain the desired fusion cells (hybridomas). Then, by repeating a sequential addition of a suitable culture liquid and centrifugation to remove the supernatant, cell fusion agents etc., that are undesirable for the growth of the hybridoma, can be removed.

[0048] Said hybridoma is selected by culturing in the conventional selection medium, for example, HAT culture medium (a culture liquid containing hypoxanthine, aminopterin, and thymidine). Culturing in said HAT culture medium is continued generally for the period of time sufficient to effect killing of the cells other than the desired hybridoma (non-fusion cells), generally several days to several weeks. The conventional limiting dilution method is conducted in which the hybridomas producing the desired antibody are screened and cloned.

[0049] In addition to obtaining the above hybridoma by immunizing an animal other than the human with an antigen, it is also possible to sensitize human lymphocytes in vitro with the desired antigen protein or antigen-expressing cells, and the resulting sensitized B-lymphocytes are fused with a myeloma cell for example U266, having the ability of dividing permanently to obtain a hybridoma that produces the desired human antibody having the activity of binding to the desired antigen or antigen-expressing cells (Japanese Post-examined Patent Publication (Kokoku) 1-59878). Furthermore, a transgenic animal having a repertoire of human antibody genes is immunized with the antigen or antigen-expressing cells to obtain the desired human antibody according to the above-mentioned method (see International Patent Application WO 93/12227, WO 92/03918, WO 94/02602, WO 94/25585, WO 96/34096 and WO 96/33735).

[0050] The monoclonal antibody-producing hybridomas thus constructed can be subcultured in the conventional culture liquid, or can be stored for a prolonged period of time in liquid nitrogen.

[0051] In order to obtain monoclonal antibodies from said hybridoma, there can be used a method in which said hybridoma is cultured in the conventional method and the antibodies are obtained as the supernatant, or a method in which the hybridoma is implanted into and grown in a mammal compatible with said hybridoma and the antibodies are obtained as the ascites. The former method is suitable for obtaining high-purity antibodies, whereas the latter is suitable for a large scale production of antibodies.

[0052] For example, an anti-IL-6 receptor antibody-producing hybridoma can be polypeptide by a method disclosed in Japanese Unexamined Patent Publication (Kokai) No. 3-139293. There may be used a method in which The PM-1 antibody-producing hybridoma that has been internationally deposited under the provisions of the Budapest Treaty on July 12, 1988 with the International Patent Organism Depository of the National Institute of Industrial Science and Technology (Central 6, 1-1-1 Higashi, Tsukuba City, Ibaraki Pref., 305-5466 Japan) as FERM BP-2998 is intraperitoneally injected to BALB/c mice to obtain ascites, from which ascites PM-1 antibody may be purified, or a method in which the hybridoma is cultured in a RPMI 1640 medium containing 10% bovine fetal serum, 5% BM-Codimed H1 (manufactured by Boehringer Mannheim), the hybridoma SFM medium (manufactured by GIBCO BRL), the PFHM-II medium (manufactured by GIBCO BRL) or the like, from the culture supernatant of which PM-1 antibody may be purified.

[0053] In accordance with the present invention, as monoclonal antibody, there can be used a recombinant antibody that was produced by cloning an antibody gene from a hybridoma and the gene is then integrated into an appropriate vector, which is introduced into a host to produce the recombinant antibody using gene recombinant technology (see, for example, Borrebaeck, C.A.K. and Larrick, J.W., THERAPEUTIC MONOCLONAL ANTIBODIES, published in the

United Kingdom by MACMILLAN PUBLISHERS LTD. 1990).

[0054] Specifically, mRNA encoding the variable region (V region) of the antibody is isolated from the cell that produces the antibody of interest, for example a hybridoma. The isolation of mRNA is conducted by preparing total RNA by a known method such as the guanidine ultracentrifuge method (Chirgwin, J.M. et al., *Biochemistry* (1979) 18, 5294-5299), the AGPC method (Chomczynski, P. et al., *Anal. Biochem.* (1987) 162, 156-159), and then mRNA is purified from the total RNA using the mRNA Purification kit (manufactured by Pharmacia) and the like. Alternatively, mRNA can be directly prepared using the Quick Prep mRNA Purification Kit (manufactured by Pharmacia).

[0055] cDNA of the V region of antibody may be synthesized from the mRNA thus obtained using a reverse transcriptase. cDNA may be synthesized using the AMV Reverse Transcriptase First-strand cDNA Synthesis Kit and the like. Alternatively, for the synthesis and amplification of cDNA, the 5'-Ampli FINDER RACE Kit (manufactured by Clontech) and the 5'-RACE method (Frohman, M.A. et al., *Proc. Natl. Acad. Sci. U.S.A.* (1988) 85, 8998-9002; Belyavsky, A. et al., *Nucleic Acids Res.* (1989) 17, 2919-2932) which employs PCR may be used. The desired DNA fragment is purified from the PCR product obtained and may be ligated to vector DNA. Moreover, a recombinant vector is constructed therefrom and then is introduced into *E. coli* etc., from which colonies are selected to prepare the desired recombinant vector. The base sequence of the desired DNA may be confirmed by a known method such as the dideoxy method.

[0056] Once DNA encoding the V region of the desired antibody has been obtained, it may be ligated to DNA encoding the constant region (C region) of the desired antibody, which is then integrated into an expression vector. Alternatively, DNA encoding the V region of the antibody may be integrated into an expression vector which already contains DNA encoding the C region of the antibody.

[0057] In order to produce antibody for use in the present invention, the antibody gene is integrated into an expression vector so as to be expressed under the control of the expression regulatory region, for example an enhancer and/or a promoter. Subsequently, the expression vector is transformed into a host cell and the antibody can then be expressed therein.

[0058] In accordance with the present invention, artificially altered recombinant antibodies such as chimeric antibody and humanized antibody can be used for the purpose of lowering heterologous antigenicity against humans. These altered antibody can be produced using known methods.

[0059] Chimeric antibody can be obtained by ligating the thus obtained DNA encoding the V region of antibody to DNA encoding the C region of human antibody, which is then integrated into an expression vector and introduced into a host for production of the antibody therein (see European Patent Application EP 125023, and International Patent Application WO 92-19759). Using this known method, chimeric antibody useful for the present invention can be obtained.

[0060] Plasmids containing the L chain V region or the H chain V region of chimeric PM-1 antibody have each been designated as pPM-k3 and pPM-h1, respectively, and *E. coli* having a respective plasmid has been internationally deposited under the provisions of the Budapest Treaty as NCIMB40366 and NCIMB40362 on February 11, 1991 with the National Collections of Industrial and Marine Bacteria Limited.

[0061] Humanized antibody which is also called reshaped human antibody has been made by implanting the complementarity determining region (CDR) of antibody of a mammal other than the human, for example mouse antibody, into the CDR of human antibody. The general recombinant DNA technology for preparation of such antibodies is also known (see European Patent Application EP 125023 and International Patent Application WO 92-19759).

[0062] Specifically, a DNA sequence which was designed to ligate the CDR of mouse antibody with the framework region (FR) of human antibody is synthesized from several divided oligonucleotides having sections overlapping with one another at the ends thereof. The DNA thus obtained is ligated to DNA encoding the C region of human antibody and then is incorporated into an expression vector, which is introduced into a host for antibody production (see European Patent Application EP 239400 and International Patent Application WO 92-19759).

[0063] For the FR of human antibody ligated through CDR, the CDR that has a favorable antigen-binding site is selected. When desired, amino acids in the FR of antibody V region may be substituted so that the CDR of humanized antibody may form an appropriate antigen binding site (Sato, K. et al., *Cancer Res.* (1993) 53, 851-856).

[0064] As the C region of human antibody, there can be used, for example, C $\gamma$ 1, C $\gamma$ 2, C $\gamma$ 3, or C $\gamma$ 4 can be used. The C region of human antibody may also be modified in order to improve the stability of antibody and of the production thereof.

[0065] Chimeric antibody consists of the V region of antibody of a human origin other than humans and the C region of human antibody, and humanized antibody consists of the complementarity determining region of antibody of a human origin other than humans and the framework region and the C region of human antibody, with their antigenicity in the human body being decreased, and thus are useful as antibody for use in the present invention.

[0066] As a preferred embodiment of humanized antibody for use in the present invention, there can be mentioned humanized PM-1 antibody (see International Patent Application WO 92-19759).

[0067] Antibody genes constructed as mentioned above may be expressed and obtained in a known manner. In the

case of mammalian cells, expression may be accomplished using a DNA in which a commonly used useful promoter, an antibody gene to be expressed, and the poly A signal have been operably linked at 3' downstream thereof, or a vector containing it. As the promoter/enhancer, for example, there can be mentioned human cytomegalovirus immediate early promoter/enhancer.

5 [0068] Additionally, as the promoter/enhancer which can be used for expression of antibody for use in the present invention, there can be used viral promoters/enhancers such as retrovirus, polyoma virus, adenovirus, and simian virus 40 (SV40), and promoters/enhancers derived from mammalian cells such as human elongation factor 1 $\alpha$  (HEF1 $\alpha$ ).

[0069] For example, expression may be readily accomplished by the method of Mulligan et al. (Mulligan, R.C. et al., Nature (1979) 277, 108-114) when SV40 promoter/enhancer is used, and by the method of Mizushima, S. et al. (Mi-

10 zushima, S. and Nagata, S., Nucleic Acids Res. (1990) 18, 5322) when HEF1 $\alpha$  promoter/enhancer is used.  
[0070] In the case of E. coli, expression may be conducted by operably linking a commonly used promoter, a signal sequence for antibody secretion, and an antibody gene to be expressed, followed by expression thereof. As the promoter, for example, there can be mentioned lacZ promoter and araB promoter. The method of Ward et al. (Ward, E.S. et al., Nature (1989) 341, 544-546; Ward, E.S. et al., FASEB J. (1992) 6, 2422-2427) may be used when lacZ promoter is used, and the method of Better et al. (Better, M. et al., Science (1988) 240, 1041-1043) may be used when araB promoter is used.

[0071] As a signal sequence for antibody secretion, when produced in the periplasm of E. coli, the pelB signal sequence (Lei, S.P. et al., J. Bacteriol. (1987) 169, 4379-4383) can be used. After separating the antibody produced in the periplasm, the structure of the antibody is appropriately refolded before use (see, for example, WO 96-30394).

20 [0072] As the origin of replication, there can be used those derived from SV40, polyoma virus, adenovirus, bovine papilloma virus (BPV), and the like. Furthermore, for amplification of the gene copy number in the host cell system, expression vectors can include as selectable markers the aminoglycoside transferase (APH) gene, the thymidine kinase (TK) gene, E. coli xanthine guaninephosphoribosyl transferase (Ecogpt) gene, the dihydrofolate reductase (dhfr) gene, and the like.

25 [0073] For the production of antibody for use in the present invention, any production system can be used, and the production systems of antibody preparation comprise the in vitro or the in vivo production system. As the in vitro production systems, there can be mentioned a production system which employs eukaryotic cells and the production system which employs prokaryotic cells.

[0074] When eukaryotic cells are used, there are the production systems which employ animal cells, plant cells, and 30 fungal cells. Known animal cells include (1) mammalian cells such as CHO cells, COS cells, myeloma cells, baby hamster kidney (BHK) cells, HeLa cells, and Vero cells, (2) amphibian cells such as Xenopus oocytes, or (3) insect cells such as sf9, sf21, and Tn5. Known plant cells include, for example, those derived from the Nicotiana tabacum which is subjected to callus culture. Known fungal cells include yeasts such as genus Saccharomyces, more specifically Saccharomyces cereviceae, or filamentous fungi such as the Aspergillus family, more specifically Aspergillus niger.

35 [0075] When prokaryotic cells are used, there are the production systems which employ bacterial cells. Known bacterial cells include Escherichia coli, and Bacillus subtilis.

[0076] By introducing, via transformation, the gene of the desired antibody into these cells and culturing the transformed cells in vitro, the antibody can be obtained. Culturing is conducted in the known methods. For example, as the culture liquid for mammalian cells, DMEM, MEM, RPMI1640, IMDM and the like can be used, and serum supplements 40 such as fetal calf serum (FCS) may be used in combination. In addition, antibodies may be produced in vivo by implanting cells into which the antibody gene has been introduced into the abdominal cavity of an animal, and the like.

[0077] As in vivo production systems, there can be mentioned those which employ animals and those which employ plants. When animals are used, there are the production systems which employ mammals and insects.

45 [0078] As mammals, goats, pigs, sheep, mice, and cattle can be used (Vicki Glaser, SPECTRUM Biotechnology Applications, 1993). Also, as insects silkworms can be used, and in the case of plants, tobacco, for example, can be used.

[0079] Antibody genes are introduced into these animals and plants, in which the genes are produced and then collected. For example, antibody genes are inserted into the middle of the gene encoding protein which is inherently produced in the milk such as goat  $\beta$  casein to prepare fusion genes. DNA fragments containing the fusion gene into 50 which the antibody gene has been inserted are injected to a goat embryo, and the embryo is introduced into a female goat. The desired antibody is obtained from the milk produced by a transgenic goat produced by the goat that received the embryo or the offspring thereof. In order to increase the amount of milk containing the desired antibody produced by the transgenic goat, hormones may be given to the transgenic goat as appropriate (Ebert, K.M. et al., Bio/Technology (1994) 12, 699-702).

55 [0080] When silkworms are used, the silkworm is infected with a baculovirus into which desired antibody gene has been inserted, and the desired antibody can be obtained from the body fluid of the silkworm (Maeda, S. et al., Nature (1985) 315, 592-594). Moreover, when tobacco is used, the desired antibody gene is inserted into an expression vector for plants, for example pMON 530, and then the vector is introduced into a bacterium such as Agrobacterium tumefa-



ciens. The bacterium is then used to infect tobacco such as *Nicotiana tabacum* to obtain the desired antibody from the leaves of the tobacco (Julian, K.-C. Ma et al., *Eur. J. Immunol.* (1994) 24, 131-138).

**[0081]** When antibody is produced in an in vitro or in vivo production systems, as mentioned above, DNA encoding the heavy chain (H chain) or light chain (L chain) of antibody is separately incorporated into an expression vector and the hosts are transformed simultaneously, or DNA encoding the H chain and the L chain of antibody is integrated into a single expression vector and the host is transformed therewith (see International Patent Application WO 94-11523).

**[0082]** Antibodies for use in the present invention may be fragments of antibody or modified versions thereof as long as they are preferably used in the present invention. For example, as fragments of antibody, there may be mentioned Fab, F(ab')<sub>2</sub>, Fv or single-chain Fv (scFv) in which Fv's of H chain and L chain were ligated via a suitable linker.

**[0083]** Specifically antibodies are treated with an enzyme, for example, papain or pepsin, to produce antibody fragments. or genes encoding these antibody fragments are constructed, and then introduced into an expression vector, which is expressed in a suitable host cell (see, for example, Co, M.S. et al., *J. Immunol.* (1994) 152, 2968-2976; Better, M. and Horwitz, A.H., *Methods Enzymol.* (1989) 178, 476-496; Plucktrun, A. and Skerra, A., *Methods Enzymol.* (1989) 178, 497-515; Lamoyi, E., *Methods Enzymol.* (1986) 121, 652-663; Rousseaux, J. et al., *Methods Enzymol.* (1986) 121, 663-669; Bird, R.E. et al., *TI BTECH* (1991) 9, 132-137).

**[0084]** scFv can be obtained by ligating the V region of H chain and the V region of L chain of antibody. In the scFv, the V region of H chain and the V region of L chain are preferably ligated via a linker, preferably a peptide linker (Huston, J.S. et al., *Proc. Natl. Acad. Sci. U.S.A.* (1988) 85, 5879-5883). The V region of H chain and the V region of L chain in the scFv may be derived from any of the above-mentioned antibodies. As the peptide linker for ligating the V regions, any single-chain peptide comprising, for example, 12 - 19 amino acid residues may be used.

**[0085]** DNA encoding scFv can be obtained using DNA encoding the H chain or the H chain V region of the above antibody and DNA encoding the L chain or the L chain V region of the above antibody as the template by amplifying the portion of the DNA encoding the desired amino acid sequence among the above sequences by the PCR technique with the primer pair specifying the both ends thereof, and by further amplifying the combination of DNA encoding the peptide linker portion and the primer pair which defines that both ends of said DNA be ligated to the H chain and the L chain, respectively.

**[0086]** Once DNAs encoding scFv are constructed, an expression vector containing them and a host transformed with said expression vector can be obtained by a conventional method, and scFv can be obtained using the resultant host by a conventional method.

**[0087]** These antibody fragments can be produced by obtaining the gene thereof in a similar manner to that mentioned above, and by allowing it to be expressed in a host. "Antibody" as used in the claim of the present application encompasses these antibody fragments.

**[0088]** As modified antibodies, antibodies associated with various molecules such as polyethylene glycol (PEG) can be used. "Antibody" as used in the claim of the present application encompasses these modified antibodies. These modified antibodies can be obtained by chemically modifying the antibodies thus obtained. These methods have already been established in the art.

**[0089]** Antibodies expressed and produced as described above can be separated from inside or outside of the cell or from the host and then may be purified to homogeneity. Separation and purification of antibody for use in the present invention may be accomplished by affinity chromatography. As the column used for affinity chromatography, there can be mentioned Protein A column and Protein G column. Examples of carriers for use in Protein A column include, for example, Hyper D, POROS, Sepharose F.F. (Pharmacia) and the like. In addition, commonly used methods of separation and purification for proteins can be used, without any limitation.

**[0090]** Chromatography other than the above affinity chromatography, filters, gel filtration, salting out, dialysis and the like may be selected and combined as appropriate, in order to separate and purify the antibodies for use in the present invention. Chromatography includes, for example, ion exchange chromatography, hydrophobic chromatography, gel-filtration and the like. These chromatographies can be applied to high performance liquid chromatography (HPLC). Also, reverse phase HPLC (rpHPLC) may be used.

**[0091]** The concentration of antibody obtained as above can be determined by measurement of absorbance or by ELISA and the like. Thus, when absorbance measurement is employed, the antibody obtained is appropriately diluted with PBS(-) and then the absorbance is measured at 280 nm, followed by calculation using the absorption coefficient of 1.35 OD at 1 mg/ml. When ELISA is used, measurement is conducted as follows. Thus, 100 µl of goat anti-human IgG antibody (manufactured by TAGO) diluted to 1 µg/ml in 0.1 M bicarbonate buffer, pH 9.6, is added to a 96-well plate (manufactured by Nunc), and is incubated overnight at 4 °C to immobilize the antibody. After blocking, 100 µl each of appropriately diluted antibody for use in the present invention or samples containing the antibody, or human IgG (manufactured by CAPPEL) as the standard is added, and incubated at room temperature for 1 hour.

**[0092]** After washing, 100 µl of 5000-fold diluted alkaline phosphatase-labeled anti-human IgG antibody (manufactured by BIO SOURCE) is added, and incubated at room temperature for 1 hour. After washing, the substrate solution is added and incubated, followed by measurement of absorbance at 405 nm using the MICROPLATE READER Model



3550 (manufactured by Bio-Rad) to calculate the concentration of the desired antibody.

**[0093]** Reshaped IL-6 for use in the present invention is a substance that has an activity of binding with IL-6 receptor and that does not propagate the biological activity of IL-6. Thus, though reshaped IL-6 competes with IL-6 for binding to IL-6 receptor, it does not propagate the biological activity of IL-6, and therefore reshaped IL-6 blocks signal transduction by IL-6.

**[0094]** Reshaped IL-6 may be prepared by introducing mutation by replacing amino acid residues of the amino acid sequence of IL-6. IL-6 from which reshaped IL-6 is derived may be of any origin, but it is preferably human IL-6 considering antigenicity etc.

**[0095]** Specifically, the secondary structure of the amino acid sequence of IL-6 may be estimated using a known molecular modeling program such as WHATIF (Vriend et al., J. Mol. Graphics (1990) 8, 52-56), and its effect on the overall amino acid residues to be replaced is evaluated. After determining suitable amino acid residues, mutation may be introduced using a vector containing a base sequence encoding human IL-6 gene as a template in a commonly used PCR method so as to replace amino acids, and thereby to obtain a gene encoding reshaped IL-6. This may be integrated, as appropriate, into a suitable expression vector to obtain reshaped IL-6 according to the above-mentioned methods for expression, production, and purification of recombinant antibody.

**[0096]** Specific examples of reshaped IL-6 has been disclosed in Brakenhoff et al., J. Biol. Chem. (1994) 269, 86-93, Saviono et al., EMBO J. (1994) 13, 1357-1367, WO 96-18648 and WO 96-17869.

**[0097]** Partial peptides of IL-6 or partial peptides of IL-6 receptor for use in the present invention are substances that have an activity of binding to IL-6 receptor or IL-6, respectively, and that do not propagate the biological activity of IL-6. Thus, partial peptides of IL-6 or partial peptides of IL-6 receptor bind to and capture IL-6 receptor or IL-6, respectively, so as to inhibit specifically the binding of IL-6 to IL-6 receptor. As a result, they do not propagate the biological activity of IL-6, and thereby block signal transduction by IL-6.

**[0098]** Partial peptides of IL-6 or partial peptides of IL-6 receptor are peptides comprising part or all of the amino acid sequence involved in the binding of IL-6 and IL-6 receptor in the amino acid sequences of IL-6 or IL-6 receptor. Such peptides comprise usually 10-80 amino acid residues, preferably 20-50 amino acid residues, and more preferably 20-40 amino acid residues.

**[0099]** Partial peptides of IL-6 or partial peptides of IL-6 receptor specify the regions involved in the binding of IL-6 and IL-6 receptor in the amino acid sequence of IL-6 or IL-6 receptor, and part or all of the amino acid sequence can be prepared by a commonly known method such as gene engineering technology or peptide synthesis.

**[0100]** In order to prepare partial peptides of IL-6 or partial peptides of IL-6 receptor by gene engineering technology, a DNA sequence encoding the desired peptide can be integrated into an expression vector so that they may be obtained according to the above-mentioned methods for expression, production, and purification of recombinant antibody.

**[0101]** In order to prepare partial peptides of IL-6 or partial peptides of IL-6 receptor by peptide synthesis, a commonly used method in peptide synthesis such as solid-phase synthesis or liquid-phase synthesis can be used.

**[0102]** Specifically, methods described in "Zoku Iyakuhiinno Kaihatsu, Vol. 14: Peptide Synthesis" edited by Haruaki Yajima, Hirokawa Shoten, 1991, can be used. As the solid-phase synthesis, there can be used a method in which an amino acid corresponding to the C-terminal of the peptide to be synthesized is bound to a support insoluble in organic solvents, and then a reaction in which amino acids of which  $\alpha$ -amino group and a side chain functional group has been protected with a suitable protecting group is condensed one by one in the direction of from the C-terminal to the N-terminal and a reaction in which said protecting group of the  $\alpha$ -amino group of the amino acid or the peptide bound to the resin is eliminated therefrom are alternately repeated to extend the peptide chain. The solid-phase peptide synthesis is roughly divided in the Boc method and the Fmoc method depending on the type of protecting groups used.

**[0103]** After thus synthesizing the peptide of interest, a deprotecting reaction or a cleavage reaction of the peptide chain from the support may be performed. For the cleavage reaction of peptide chains, the Boc method employs hydrogen fluoride or trifluoromethanesulfonic acid, or the Fmoc method usually employs TFA. In the Boc method, the above protected peptide resin is treated in the presence of anisole in hydrogen fluoride. Subsequently, the elimination of the protecting group and the cleavage from the support may be performed to collect the peptide. Lyophilization of this yields crude peptide. On the other hand, in the Fmoc method, the deprotection reaction and the cleavage reaction of the peptide chain from the support may be performed in a manner similar to the one mentioned above.

**[0104]** The crude peptide obtained may be subjected to HPLC to separate and purify it. In its elution, a water-acetonitrile solvent commonly used in protein purification may be used under an optimal condition. Fractions corresponding to the peaks of the chromatographic profile is harvested and then lyophilized. For the peptide fractions thus purified, molecular weight analysis by mass spectroscopy, analysis of amino acid composition, or analysis of amino acid sequence is performed for identification.

**[0105]** Specific examples of IL-6 partial peptides and IL-6 receptor partial peptides have been disclosed in Japanese Unexamined Patent Publication (Kokai) No. 2-188600, Japanese Unexamined Patent Publication (Kokai) No. 7-324097, Japanese Unexamined Patent Publication (Kokai) No. 8-311098, and U.S. Pat. Publication US 5210075.

**[0106]** The inhibitory activity of IL-6 signal transduction by IL-6 antagonist of the present invention can be evaluated

using a commonly known method. Specifically, IL-6-dependent HN60.BSF2 cells are cultured, to which IL-6 is added, and at the same time, in the presence of IL-6 antagonist, the incorporation of  $^3\text{H}$  labeled thymidine by the IL-6 dependent cells is determined. Alternatively,  $^{125}\text{I}$ -labeled IL-6 and IL-6 antagonist, at the same time, are added, and then  $^{125}\text{I}$ -labeled IL-6 that bound to the IL-6-expressing cells is determined for evaluation. In the above assay system, in addition to the group in which the IL-6 antagonist is present, a negative control group in which contains no IL-6 antagonist is set up, and the results obtained in both are compared to evaluate the IL-6-inhibiting activity by IL-6 antagonist.

**[0107]** In order to confirm the effects of the present invention, the IL-6 antagonist for use in the present invention is administered to an animal that developed psoriasis-like lesions after being implanted with  $\text{CD4}^+$   $\text{CD45RB}^{\text{high}}$  T cells, and the skin tissue is observed to evaluate the improvement in the psoriasis-like lesions.

**[0108]**  $\text{CD4}^+$   $\text{CD45RB}^{\text{high}}$  T cells for inducing psoriasis-like lesions can be prepared from, for example, F2 (BALB/c x 129/SvJ) mouse spleen, by a method described in Examples hereinbelow. Also, as animals in which psoriasis-like lesions are induced, for example, mice, preferably SCID mice, may be used.

**[0109]** As shown in Examples below, since improvement in psoriasis-like lesions was observed by administration of anti-IL-6 receptor antibody in animals that developed psoriasis, IL-6 antagonists such as anti-IL-6 receptor antibody were shown to have a therapeutic effect for psoriasis.

**[0110]** Subjects to be treated in the present invention are mammals. Subject mammals to be treated are preferably humans.

**[0111]** Preventive or therapeutic agents of the present invention may be administered orally or parenterally and systemically or locally. For example, intravenous injection such as drip infusion, intramuscular injection, intraperitoneal injection, subcutaneous injection, suppositories, enema, oral enteric coated tablets, and the like may be selected, and the dosage regimen may be selected as appropriate depending on the age and conditions of the patient. The effective dose is chosen from the range of 0.01 mg to 100 mg per kg of body weight per administration. Alternatively, the dosage of 1 to 1000 mg, preferably 5 to 50 mg per patient may be selected.

**[0112]** Preventive or therapeutic agents of the present invention may contain pharmaceutically acceptable carriers and additives depending on the route of administration. Examples of such carriers or additives include water, a pharmaceutically acceptable organic solvent, collagen, polyvinyl alcohol, polyvinylpyrrolidone, a carboxyvinyl polymer, carboxymethylcellulose sodium, polyacrylic sodium, sodium alginate, water-soluble dextran, carboxymethyl starch sodium, pectin, methyl cellulose, ethyl cellulose, xanthan gum, gum Arabic, casein, gelatin, agar, diglycerin, propylene glycol, polyethylene glycol Vaseline, paraffin, stearyl alcohol, stearic acid, human serum albumin (HSA), mannitol, sorbitol, lactose, pharmaceutically acceptable surfactants and the like. Actual additives used are chosen from, but not limited to, the above or combinations thereof depending on the dosage form.

#### Examples

**[0113]** The present invention will now be explained hereinbelow in more detail with reference to the following working examples, reference examples, and experimental examples. It is to be noted, however, that the present invention is not limited to these examples in any way.

#### Working Example

##### Method

**[0114]** After spleen cells of BALB/c mice were hemolyzed according to the method of Schon MP et al. (Nature Medicine (1997) 3, 183-188),  $\text{CD4}^+$   $\text{CD45RB}^{\text{high}}$  T cells were prepared using the MACS column and the FACS Vantage, and were i.p. implanted to C.B-17 scid mice at  $4.0 \times 10^5$  cells/head.

**[0115]** Fifteen minutes after the cell implantation, anti-IL-6 receptor antibody (MR16-1) was i.p. administered at 2 mg/head. The negative control and the positive control groups (non-cell implantation group and the cell implantation group) received PBS. Subsequently, MR16-1 was administered at 1 mg/head/week, and at about eight weeks after cell implantation, mice were euthanized, and the ears were collected and fixed in formalin. According to a standard method, histological specimens were prepared and HE-stained. Then, the skin tissue of the ear was observed and psoriasis-like lesions were assessed by the scores according to the following criteria:

- : Normal,
- +/-: Mild acanthosis is seen,
- +: Acanthosis is seen,
- ++: Marked acanthosis is seen.

**[0116]** Statistical analysis was performed by SAS by Wilcoxon's rank sum test with a level of significance of 5%.

## Results

[0117] As can be seen in Table 1, significant increase in the score of psoriasis-like lesions was observed by the implanting of the cells, and the establishment of the experimental system was demonstrated. By administering an anti-IL-6 receptor antibody, MR16-1, to the cell implantation group, significant improvement in the score of psoriasis-like lesions was observed. The foregoing has shown a possibility that anti-IL-6 receptor antibody could be a novel therapeutic agent for psoriasis.

Table 1

Assessment of histological tissues					
Group	Score of psoriasis-like lesions				Wilcoxon's rank sum test
	-	±	+	++	
Non-cell implantation group (n=8)	7	1	0	0	
Cell implantation group (n=7)	2	0	2	3	P=0.0126, vs non-cell implantation group
cell implantation + MR16-1 administration group (n=5)	5	0	0	0	P=0.0221, vs cell implantation group

## Reference example 1. Preparation of human soluble IL-6 receptor

[0118] Using a plasmid pBSF2R.236 containing cDNA that encodes IL-6 receptor obtained by the method of Yamasaki et al. (Yamasaki et al., Science (1988) 241, 825-828), soluble IL-6 receptor was prepared by the PCR method. The plasmid pBSF2R.236 was digested with a restriction enzyme Sph I to obtain IL-6 receptor cDNA, which was inserted into mp18 (manufactured by Amersham). Using a synthetic primer designed to introduce a stop codon into IL-6 receptor cDNA, mutation was introduced into IL-6 receptor cDNA by the PCR method in an in vitro mutagenesis system (manufactured by Amersham). By this procedure, the stop codon was introduced at the position of amino acid 345, and cDNA encoding soluble IL-6 receptor was obtained.

[0119] In order to express soluble IL-6 receptor in CHO cells, it was ligated to a plasmid pSV (manufactured by Pharmacia) to obtain a plasmid pSVL344. Soluble IL-6 receptor cDNA digested with HindIII-Sall was inserted into a plasmid pCEdhfr containing the cDNA of dhfr to obtain a CHO cell-expressing plasmid pCEdhfr344.

[0120] Ten µg of plasmid pCEdhfr344 was transfected to a dhfr-CHO cell line DXB-11 (Urlaub, G. et al., Proc. Natl. Acad. Sci. USA (1980) 77, 4216-4220) by the calcium phosphate precipitation method (Chen, C. et al., Mol. Cell. Biol. (1987) 7, 2745-2751). The transfected CHO cells were cultured for three weeks in a nucleoside-free αMEM selection medium containing 1 mM glutamine, 10% dialyzed FCS, 100 U/ml penicillin and 100 µ/ml streptomycin.

[0121] The selected CHO cells were screened by the limiting dilution method to obtain a single CHO cells clone. The CHO cell clone was amplified with 20 nM - 200 nM of methotrexate to investigate a human soluble IL-6 receptor-producing CHO cell line 5E27. The CHO cell line 5E27 was cultured in a Iscov modified Dulbecco medium (IMDM, manufactured by Gibco) supplemented with 5% FBS. The culture supernatant was collected and the concentration of soluble IL-6 receptor in the culture supernatant was determined by ELISA. The result confirmed the presence of soluble IL-6 receptor in the culture supernatant.

## Reference Example 2. Preparation of anti-human IL-6 antibody

[0122] Ten µg of tissue-type IL-6 (Hirano et al., Immunol. Lett. (1988) 17, 41) was used with Freund's complete adjuvant to immunize BALB/c mice, and this was repeated every week until anti-IL-6 antibody can be detected in the serum. Immune cells were removed from the local lymph nodes, and were fused with a myeloma cell line P3U1 using polyethylene glycol 1500. Hybridomas were selected by the method of Oi et al. (Selective Methods in Cellular Immunology, W.H. Freeman and Co., San Francisco, 351, 19080) using the HAT culture medium to establish a hybridoma producing anti-human IL-6 antibody.

[0123] The hybridoma producing anti-human IL-6 antibody was subjected to an IL-6 binding assay in the following manner. Thus, a 96-well microtiter plate (manufactured by Dynatech Laboratories, Inc., Alexandria, VA) made of flexible polyvinyl was coated overnight with 100 µl of goat anti-mouse Ig (10 µl/ml, manufactured by Cooper Biomedical, Inc., Malvern, PA) in 0.1 M carbonate hydrogen carbonate buffer (pH 9.6) at 4°C. Then, the plate was treated in 100 µl of PBS containing 1% bovine serum albumin (BSA) at room temperature for 2 hours.

[0124] After this was washed in PBS, 100 µl of the hybridoma culture supernatant was added to each well, and

incubated overnight at 4°C. After washing the plate,  $^{125}\text{I}$ -labelled recombinant type IL-6 was added to each well to 2000 cpm/0.5 ng/well, and after washing, radioactivity of each well was measured by a gamma counter (Beckman Gamma 9000, Beckman Instruments, Fullerton, CA). Of 216 hybridoma clones, 32 hybridoma clones were positive in the IL-6 binding assay. From among these clones, finally MH166.BSF2, a stable clone, was selected. Anti-IL-6 antibody MH166 has a subtype of IgG1  $\kappa$  type.

[0125] Then, using a IL-6-dependent mouse hybridoma clone MH60.BSF2, a neutralizing activity with regard to the growth of the hybridoma by MH166 antibody was investigated. MH60.BSF2 cells were aliquoted to  $1 \times 10^4/200 \mu\text{l/well}$ , to which a sample containing MH166 antibody was added, and cultured for 48 hours. After adding 0.5  $\mu\text{Ci/well}$  of  $^3\text{H}$ -thymidine (New England Nuclear, Boston, MA), culturing was continued for further six hours. The cells were placed on a glass filter paper, and were treated by an automated harvester (Labo Mash Science Co., Tokyo, Japan). As the control, rabbit anti-IL-6 antibody was used.

[0126] As a result, MH166 antibody inhibited  $^3\text{H}$ -thymidine incorporation by MH60.BSF2 cells induced by IL-6 in a dose dependent manner. This revealed that MH166 antibody neutralizes the activity of IL-6. Reference Example 3. Preparation of anti-human IL-6 receptor antibody

[0127] Anti-IL-6 receptor antibody MT18 prepared by the method of Hirata et al. (Hirata, Y. et al., J. Immunol. (1989) 143, 2900-2906) was conjugated to a CNBr-activated Sepharose 4B (manufactured by Pharmacia Fine Chemicals, Piscataway, NJ) to purify IL-6 receptor (Yamasaki et al., Science (1988) 241, 825-828). A human myeloma cell line U266 was solubilized with 1 mM p-paraaminophenylmethanesulfonyl fluoride hydrochloride (manufactured by Wako Pure Chemicals) (digitonin buffer) containing 1% digitonin (manufactured by Wako Pure Chemicals), 10 mM triethanolamine (pH 7.8), and 0.15 M NaCl, and was mixed with MT18 antibody conjugated to Sepharose 4B beads. Subsequently, the beads were washed six times in the digitonin buffer to prepare a partially purified IL-6 receptor.

[0128] BALB/c mice were immunized with the above partially purified IL-6 receptor obtained from  $3 \times 10^9$  U266 cells four times every ten days, and then a hybridoma was prepared according to a standard method. The culture supernatant of the hybridoma from growth-positive wells were examined for the binding activity to IL-6 receptor in the following manner.  $5 \times 10^7$  U266 cells were labelled with  $^{35}\text{S}$ -methionine (2.5 mCi), and were solubilized with the above digitonin buffer. The solubilized U266 cells were mixed with 0.04 ml of MT18 antibody conjugated to Sepharose 4B beads, and then washed for six times in the digitonin buffer. Using 0.25 ml of the digitonin buffer (pH 3.4),  $^{35}\text{S}$ -methionine-labeled IL-6 receptor was eluted, which was neutralized with 0.025 ml of 1M Tris, pH 7.4.

[0129] 0.05 ml of the hybridoma culture supernatant was mixed with 0.01 ml Protein G Sepharose (manufactured by Pharmacia). After washing, the Sepharose was incubated with 0.005 ml solution of  $^{35}\text{S}$ -labeled IL-6 receptor solution. The immunoprecipitated substances were analyzed by SDS-PAGE to study the culture supernatant of hybridoma that reacts with IL-6 receptor. As a result, a reaction-positive hybridoma clone PM-1 was established. Antibody produced from the hybridoma PM-1 had the IgG1  $\kappa$  subtype.

[0130] The activity of the antibody produced by the hybridoma PM-1 to inhibit the binding of IL-6 to IL-6 receptor was evaluated using a human myeloma cell line U266. Human recombinant IL-6 was prepared from E. coli (Hirano et al., Immunol. Lett. (1988) 17, 41-45), and was labeled with  $^{125}\text{I}$  using the Bolton-Hunter reagent (New England Nuclear, Boston, MA) (Taga et al., J. Exp. Med. (1987) 166, 967-981).

[0131]  $4 \times 10^5$  U266 cells were cultured with a culture supernatant of 70%(v/v) hybridoma PM-1 and 14000 CPM of  $^{125}\text{I}$ -labeled IL-6 for one hour. Seventy microliters of a sample was layered onto 300  $\mu\text{l}$  of FCS in a 400  $\mu\text{l}$  microfuge polyethylene tube, centrifuged, and then the radioactivity of the cells were measured.

[0132] The result revealed that the antibody produced by the hybridoma PM-1 inhibits the binding of IL-6 to IL-6 receptor.

#### Reference example 4. Preparation of anti-mouse IL-6 receptor antibody

[0133] A monoclonal antibody against mouse IL-6 receptor was prepared by the method of Saito, T. et al., J. Immunol. (1991) 147, 168-173.

[0134] CHO cells that produce soluble mouse IL-6 receptor were cultured in an IMDM culture medium supplemented with 10% FCS. From the culture supernatant, soluble mouse IL-6 receptor was purified using an affinity column in which anti-mouse IL-6 receptor antibody RS12 (see the above Saito, T. et al.) was immobilized to the Affigel 10 gel (manufactured by Biorad).

[0135] Fifty  $\mu\text{g}$  of soluble mouse IL-6 receptor thus obtained was mixed with Freund's complete adjuvant, which was intraperitoneally injected to the abdomen of Wistar rats. Two weeks later, the rats received booster immunization with Freund's incomplete adjuvant. On day 45, spleen cells were removed from the rats, and  $2 \times 10^8$  cells of them were subjected to cell fusion with  $1 \times 10^7$  mouse myeloma cells P3U1 with 50% PEG1500 (manufactured by Boehringer Mannheim) using a standard method, and the hybridoma were then screened with the HAT medium.

[0136] After adding the culture supernatant to a plate coated with rabbit anti-rat IgG antibody (manufactured by Cappel), soluble mouse IL-6 receptor was reacted thereto. Then, using an ELISA method employing rabbit anti-mouse

IL-6 receptor antibody and alkaline phosphatase-labelled sheep anti-rabbit IgG, hybridomas that produce antibodies against soluble mouse IL-6 receptor were screened. The hybridoma clones for which antibody production was confirmed were subjected to subscreening twice to obtain a single hybridoma clone. This clone was designated as MR16-1.

[0137] A neutralizing activity in signal transduction of mouse IL-6 by the antibody produced by this hybridoma was examined using  $^3\text{H}$ -thymidine incorporation that employs MH60.BSF2 cells (Matsuda, T. et al., J. Immunol. (1988) 18, 951-956). To a 96-well plate, MH60.BSF2 cells were prepared to  $1 \times 10^4$  cells/200  $\mu\text{l}$ /well. To this plate were added 10 pg/ml of mouse IL-6 and MR16-1 antibody or RS12 antibody at 12.3-1000 ng/ml, and cultured at  $37^\circ\text{C}$  in 5%  $\text{CO}_2$  for 44 hours, followed by the addition of 1  $\mu\text{Ci}$ /well of  $^3\text{H}$ -thymidine. Four hours later, the incorporation of  $^3\text{H}$ -thymidine was measured. As a result, MR16-1 antibody inhibited the  $^3\text{H}$ -thymidine incorporation by MH60.BSF2 cells.

[0138] Thus, it was revealed that antibody produced by the hybridoma MR16-1 inhibits the binding of IL-6 to IL-6 receptor.

#### Industrial Applicability

[0139] The present invention indicated that IL-6 antagonists such as anti-IL-6 receptor antibody have a therapeutic effect on psoriasis. Thus, it was revealed that IL-6 antagonists are effective as therapeutic agents for psoriasis etc.

[0140] Reference to microorganisms deposited under Rule 13-2

#### International depository authority

[0141] Name: National Institute of Industrial Science and Technology, International Patent Organism Depository

[0142] Address: Central 6, 1-1-1 Higashi, Tsukuba City, Ibaraki Pref., 305-5466 Japan

[0143] Date deposited and deposit number:

(1) Name of Organism deposited: HB101-pIBBSF2R Date deposited: January 9, 1989

Accession number: FERM BP-2232

(2) Name of Organism deposited: PM1 Date deposited: July 12, 1989

Accession number: FERM BP-2998

(3) Name of Organism deposited: Rat-mouse hybridoma MR16-1

Date deposited: March 13, 1997 Accession number: FERM BP-5875

#### Claims

1. A preventive or therapeutic agent for psoriasis comprising interleukin-6 (IL-6) antagonist as an active ingredient.
2. The preventive or therapeutic agent according to claim 1, in which the IL-6 antagonist is an antibody against IL-6 receptor.
3. The preventive or therapeutic agent according to claim 2, in which the antibody against IL-6 receptor is a monoclonal antibody against IL-6 receptor.
4. The preventive or therapeutic agent according to claim 3, in which the antibody against IL-6 receptor is a monoclonal antibody against human IL-6 receptor.
5. The preventive or therapeutic agent according to claim 3, in which the antibody against IL-6 receptor is a monoclonal antibody against mouse IL-6 receptor.
6. The preventive or therapeutic agent according to any one of claims 2-5, in which the antibody against IL-6 receptor is a recombinant antibody.
7. The preventive or therapeutic agent according to claim 4, in which the monoclonal antibody against human IL-6 receptor is PM-1 antibody.
8. The preventive or therapeutic agent according to claim 5, in which the monoclonal antibody against mouse IL-6 receptor is MR16-1 antibody.
9. The preventive or therapeutic agent according to any one of claims 2-4, in which the antibody against IL-6 receptor

is a chimeric antibody or a humanized antibody against IL-6 receptor.

10. The preventive or therapeutic agent according to claim 9, in which the humanized antibody against IL-6 receptor is a humanized PM-1 antibody.
- 5 11. Use of an interleukin-6 (IL-6) antagonist for the production of a preventive and therapeutic agent for psoriasis.
12. The use according to claim 11, in which the IL-6 antagonist is an antibody against IL-6 receptor.
- 10 13. The use according to claim 12, in which the antibody against IL-6 receptor is a monoclonal antibody against IL-6 receptor.
14. The use according to claim 13, in which the antibody against IL-6 receptor is a monoclonal antibody against human IL-6 receptor.
- 15 15. The use according to claim 13, in which the antibody against IL-6 receptor is a monoclonal antibody against mouse IL-6 receptor.
16. The use according to any one of claims 12-15, in which the antibody against IL-6 receptor is a recombinant antibody.
- 20 17. The use according to claim 14, in which the monoclonal antibody against human IL-6 receptor is PM-1 antibody.
18. The use according to claim 15, in which the monoclonal antibody against mouse IL-6 receptor is MR16-1 antibody.
- 25 19. The use according to any one of claims 12-14, in which the antibody against IL-6 receptor is a chimeric antibody or a humanized antibody against IL-6 receptor.
20. The use according to claim 19, in which the humanized antibody against IL-6 receptor is a humanized PM-1 antibody.
- 30 21. A method of preventing or treating psoriasis comprising administering an interleukin-6 (IL-6) antagonist to a subject.
22. The method according to claim 21, in which the IL-6 antagonist is an antibody against IL-6 receptor.
- 35 23. The method according to claim 22, in which the antibody against IL-6 receptor is a monoclonal antibody against IL-6 receptor.
24. The method according to claim 23, in which the antibody against IL-6 receptor is a monoclonal antibody against human IL-6 receptor.
- 40 25. The method according to claim 23, in which the antibody against IL-6 receptor is a monoclonal antibody against mouse IL-6 receptor.
26. The method according to any one of claims 22-25, in which the antibody against IL-6 receptor is a recombinant antibody.
- 45 27. The method according to claim 24, in which the monoclonal antibody against human IL-6 receptor is PM-1 antibody.
28. The method according to claim 25, in which the monoclonal antibody against mouse IL-6 receptor is MR16-1 antibody.
- 50 29. The method according to any one of claims 22-24, in which the antibody against IL-6 receptor is a chimeric antibody or a humanized antibody against IL-6 receptor.
- 55 30. The method according to claim 29, in which the humanized antibody against IL-6 receptor is a humanized PM-1 antibody.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP01/09409

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> Int.Cl <sup>7</sup> A61K45/00, 39/395, A61P17/06  According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) Int.Cl <sup>7</sup> A61K45/00, 39/395, A61P17/06  Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Jitsuyo Shinan Koho 1940-1992 Toroku Jitsuyo Shinan Koho 1994-1996 Kokai Jitsuyo Shinan Koho 1971-1992 Jitsuyo Shinan Toroku Koho 1996-2002  Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAPLUS (STN), BIOSIS (STN), MEDLINE (STN), EMBASE (STN)		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Atsushi OGATA, et al., Cytokine: esp. IL-6 no Kenkyu no Shinpo to Rinsho Ouyou, Rinsho Byouri, 1999, Vol.47, No.4, pp.321-326, Full text, esp., ABSTRACT, Chapters VI, VIII	1-20
Y	Takagi, Nobuhiro et al., Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis, Arthritis Rheum. 1998, Vol.41, No.12, pp.2117-2121	1-20
Y	EP 409607 A2 (Kishimoto, Tadimitsu), 23 January, 1991 (23.01.1991), & JP 3-139293 A & US 5670373 A	1-20
X	EP 448181 A2 (Gist-Brocades N. V.), 25 September, 1991 (25.09.1991), whole document, especially p.8, right column, line 38 & JP 8-99996 A	1
X	WO 94/8574 A1 (Otsuka America Pharmaceutical, Inc.), 28 April, 1994 (28.04.1994), whole document, especially, Claim 20	1
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 22 January, 2002 (22.01.02)		Date of mailing of the international search report 05 February, 2002 (05.02.02)
Name and mailing address of the ISA/ Japanese Patent Office		Authorized officer
Facsimile No.		Telephone No.

Form PCT/ISA/210 (second sheet) (July 1992)



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP01/09409

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	& EP 664700 A1 & JP 8-502295 A & US 5453444 A	

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP01/09409

**Box I** Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 21-30  
because they relate to subject matter not required to be searched by this Authority, namely:  
Claims 21 to 30 pertain to methods for treatment of the human body by therapy and thus relate to a subject matter which this International Searching Authority is not required, under the provisions of Article 17(2)(a)(i) of the PCT and Rule 39.1(iv) of the Regulations under the PCT, to search.
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II** Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1992)

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP01/09409

Claims 1 and 11 relate to preventives or remedies for psoriasis containing as the active ingredient a compound which is defined by a desired property, i.e., "interleukin-6 antagonist". Thus, claims 1 and 11 involve any compounds having such property in the scope. However, it is recognized that only small part of the claimed compounds are exclusively supported by the description under the provision of Article 6 of the PCT and disclosed therein under the provision of Article 5 of the PCT.

Even though the common technical knowledge at the point of the application is taken into consideration, it cannot be recognized that the scope of compounds having such property of "interleukin-6 antagonist" could be specified. Thus, claims 1 and 11 also fail to satisfy the requirement of clearness as defined in Article 6 of the PCT.

Therefore, the search has been practiced mainly on the relation between interleukin-6 agonist and psoriasis and remedies for psoriasis containing as the active ingredient the antibodies as set forth in claims 2 to 10 which are specifically cited in the description.